Sareum Holdings (SAR)


Latest News

SRA737 trial update in Sierra Oncology Q1 Results

RNS Number: 6866N Sareum Holdings PLC 10 May 2018 (AIM: SAR) 10 May 2018 This announcement contains inside information for the purposes of Article 7 of Regulation 596/2014 SAREUM HOLDINGS PLC ("Sareum" or "the Company") Sareum notes that Sierra Oncology has confirmed the start of the cohort expansion Phase 2 trial evaluating SRA737 plus gem...

Sareum to Present at BioTrinity 2018 in London

RNS Number: 8341L Sareum Holdings PLC 24 April 2018 (AIM: SAR) 24 April 2018 Sareum Holdings PLC ("Sareum" or the "Company") Sareum to Present at BioTrinity 2018 in London Sareum Holdings plc (AIM:SAR) , the specialist cancer drug discovery and development business , will present at BioTrinity 2018 in London today, at 12.20pm. Dr Tim Mitchell, CEO o...

AACR 2018 Update

RNS Number: 1966L Sareum Holdings PLC 17 April 2018 (AIM: SAR) 17 April 2018 SAREUM HOLDINGS PLC ("Sareum" or "the Company") Sareum Notes that Sierra Oncology will Present Late-Breaking Data Demonstrating SRA737 Preclinical Activity with PARP Inhibitors at the AACR 2018 Annual Meeting Two posters reporting activity for SRA737 with PARP...

Late-breaker abstract for SRA737 accepted for AACR

RNS Number: 7737H Sareum Holdings PLC 15 March 2018 (AIM: SAR) 15 March 2018 SAREUM HOLDINGS PLC ("Sareum" or "the Company") Sareum notes Sierra Oncology announcement that a late-breaking abstract reporting SRA737 preclinical activity in CCNE1-driven and PARP inhibitor-resistant cancers has been accepted for AACR 2018 Annual Meeting S...

All News

10-05-18SRA737 trial update in Sierra Oncology Q1 ResultsRNS
24-04-18Sareum to Present at BioTrinity 2018 in LondonRNS
17-04-18AACR 2018 UpdateRNS
15-03-18Late-breaker abstract for SRA737 accepted for AACRRNS
13-03-18Interim ResultsRNS
27-02-18Sierra Oncology expands SRA737 development programRNS
22-02-18Preclinical synergy of sra737 and PARP inhibitorRNS
13-02-18Notice of Interim ResultsRNS
20-12-17Issue of OptionsRNS
19-12-17Sareum announces new patent approvalStockMarketWire
19-12-17Patent Grants in Japan & China for TYK2 InhibitorsRNS
14-12-17Result of AGMRNS
14-12-17Sareum reports 'significant' year of progressStockMarketWire
14-12-17AGM StatementRNS
20-11-17Notice of AGM and Annual Report & AccountsRNS
31-10-17Sareum notes experiment progressStockMarketWire
31-10-17Sierra Reports Preclinical Data for Chk1 InhibitorRNS
19-10-17Sareum reports maiden profit of £400,000StockMarketWire
19-10-17Final ResultsRNS
09-10-17Sierra Oncology host KOL Meeting on 12 Oct in NYRNS
18-09-17Sierra Oncology to host call on Chk1 inhibitorRNS
22-08-17Sareum profit after tax anticipated to beat expectationsStockMarketWire
22-08-17Pre-Close Trading StatementRNS
19-06-17Sareum to Present at the ICCS 2017RNS
05-06-17Sareum updates on Chk1 inhibitor trialsStockMarketWire
05-06-17Chk1 Clinical Trials UpdateRNS
31-05-17Sareum Holdings notes Sierra Oncology patentsStockMarketWire
31-05-17Sierra Oncology Granted US and EU PatentsRNS
25-05-17Sierra Oncology to Present at ASCO Annual MeetingRNS
09-05-17Sareum to Present at BioTrinity 2017RNS
09-03-17Director Deals - Sareum Holdings PLC (SAR)StockMarketWire
09-03-17Director ShareholdingRNS
20-02-17Sareum swings to H1 pretax profitStockMarketWire
20-02-17Half-year ResultsRNS
09-02-17Notice of Interim ResultsRNS
09-01-17Milestone Payment from Chk1 Licence AgreementRNS
22-12-16Result of General MeetingRNS
15-12-16Result of AGMRNS
06-12-16Directors' Remuneration & General MeetingRNS

RSS feeds

  • Editorial news feed for LSE:SAR Editorial
  • Regulatory news feed for LSE:SAR Regulatory